Merz Aesthetics® Launches Ultherapy PRIME® in the EMEA Region at the 2025 IMCAS World Congress

23.1.2025 09:00:00 CET | Business Wire | Press release

New Data is presented in the field of regenerative aesthetics

Merz Aesthetics launches Ultherapy PRIME^® in Europe, Middle East and Africa, an evolution of the non-invasive skin lifting Ultherapy^® and presents six abstracts at the 2025 International Master Course on Aging Science (IMCAS) World Congress highlighting its product portfolio and its contribution to the field of regenerative aesthetics.

“Our new Ultherapy PRIME^® device demonstrates our commitment to persist in innovation,” said Gonzalo Mibelli, EMEA President, Merz Aesthetics. “As one of the leaders in non-invasive lifting, we’re excited to bring Ultherapy PRIME to our customers as the next generation, premier platform as a proven technology and customizable, long-lasting* treatment option.”

The focus of this year’s Merz Aesthetics Symposium at IMCAS is Regenerative Aesthetics. “Patients are looking for more sustainable ways to address aging with regenerative aesthetic treatments providing both preventive and restorative methods to improve skin health and enhance long-term confidence,” said Dr. Kerstin Olsson, Head of Medical Affairs EMEA at Merz Aesthetics. “By collaborating with experts in aesthetics and aging science, this year’s Congress enables us to showcase our advancements and leadership in this field.”

Merz Aesthetics organized a program led by notable medical aesthetic experts, participating in various IMCAS sessions and presenting new data throughout the event.

Merz Aesthetics Symposium RegenX: Elevating Skin, Lifting Confidence. – Dr. Joyce Lim, Dr. Julia Sevi, Dr. Tatjana Pavicic, Dr. Omar Haroon, Dr. Daria Voropai, Saturday, February 1, 10:30 – 12:30
Ultherapy PRIME^® Golden Lounge:
- Opening with Dr. Sabrina Fabi, Thursday, January 30, 12:30
- Expert Roundtable “Non-invasive Regenerative Biostimulation” – Dr. Tatjana Pavicic, Dr. Kerstin Ortlechner, Dr. Sonja Sattler, Thursday, January 30, 14:30
- Expert Roundtable “Importance of Visualization” – Dr. Julia Sevi, Dr. Daria Voropai, Dr. Kerstin Ortlechner, Friday, January 31, 10:00
- Expert Talk “Truly non-invasive Regenerative Collagen Biostimulation” – Dr. Tatjana Pavicic, Dr. Alec McCarthy, Friday, January 31, 12:45
IMCAS Product Analysis Session “HA Skinboosters” – Dr. Mimi Borelli, Global Medical Affairs, Merz Aesthetics, Thursday, January 30, 13:30 – 15:00
IMCAS Economic Tribune Roundtable – Bob Rhatigan, CEO, Merz Aesthetics, Friday, January 31, 16:00 – 18:00
IMCAS Product Analysis Session “Aesthetic Toxins: Pipeline & Future” – Andy Curry, PhD, Associate Medical Director, Merz Aesthetics, Saturday, February 1, 14:00 ‒ 15:30

Merz Aesthetics Booth Talks

Connecting with Confidence: Global Insights for a more patient centered approach – Dr. Shannon Humphrey, Thursday, January 30, 14:30
The power of synergy for challenging cases – Dr. Larisa Pfahl, Thursday, January 30, 15:30
Standing out in a competitive marketplace: Building an influential brand in Aesthetics – Dr. Audrey Neff, Friday, January 31, 11:00
2 is better than 1: Optimizing Results – Dr. Chris Hutton, Friday, January 31, 13:00
Synergistic strategies for décolleté treatment in mature patients – Dr. Marie-Eugénie Nichanian-Broglia, Friday, January 31, 13:30
Enhancing Skin Quality: Case study and clinical outcome – Dr. Tatiana Kuznechenkova, Friday, January 31, 15:30

E-Poster Presentations

Virtual posters will be available for viewing on-site throughout the Congress and displayed on the virtual e-poster platform with detailed abstracts.

CaHA microspheres stimulate proteoglycan expression, supporting improved skin quality and elasticity. Authors: Yoana Dimitrova, MSc; Christian Hartmann, PhD; Kristina Riegel, PhD; Daniela Schäfer, PhD; Christina Wollenburg, PhD; Kay Marquardt, PhD; Thomas Hengl; PhD
Exploring the mode of action of elastin stimulation by CaHA microspheres. Authors: Christian Hartmann, PhD; Kristina Riegel, PhD; Yoana Dimitrova, MSc; Daniela Schäfer, PhD; Christina Wollenburg, PhD; Kay Marquardt, PhD; Thomas Hengl, PhD
Global Perspectives on Aesthetic Treatments and Approaches for Skin Quality Improvement: Insights from an Expert Advisory Board. Authors: Martina Kerscher, MD; Kate Goldie, MD; Cyro Hirano, MD; Stephen Lowe, MD; Kavita Mariwalla, MD; Milton Moore, MD; Je Young Park, MD; Dusan Sajic, MD; Sonja Sattler, MD; Julieta Spada, MD; Vasanop Vachiramon, MD; Bianca Viscomi, MD
Microfocused Ultrasound in Regenerative Aesthetics: A Narrative Review on Mechanisms of Action and Clinical Outcomes. Authors: Vasanop Vachiramon, MD; Tatjana Pavicic, MD; Gabriela Casabona, MD; Jeremy B. Green, MD; Jennifer Levine, MD; Je Young Park, MD; Julieta Spada, MD; Mariana Muniz, MD; John Akers, PharmD; Matthew Jackson, PhD; Alec McCarthy, PhD
Arterioembolic Characteristics of Hyaluronic Acid and Calcium Hydroxylapatite Fillers within an Artificial Arterial Perfusion Model. Authors: Alec D. McCarthy, PhD; Danny J. Soares, MD; Akash Chandawarkar, MD; Julia Fedorova, MS-I; Yu Zhang, MS-I; Larry Blevins, PA-C; Alexis Bowhay, PA-C; Thomas J. Kean, PhD; David K. Funt, MD
Extracellular Matrix Response to Diluted Calcium Hydroxylapatite Microspheres and Poly-L-Latic Acid Microparticles. Authors: Gabriela Casabona, MD; Kate Goldie, MD; Niamh Corduff, MD; Alec McCarthy, PhD; Korin Leffler, PhD; Thomas Hengl, PhD; Kristina Riegel, PhD

*results can last up to a year or more, Werschler et al. Long-term efficacy of micro-focused ultrasound with visualization for lifting and tightening lax facial and neck skin using a customized vectoring treatment method. J Clin Aesthet Dermatol. 2016;(9)2:27-33, Ulthera Instructions For Use.

About Merz Aesthetics

Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves — however they define it. Clinically proven, its product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with high standards of safety and efficacy. Being family owned for more than 115 years, Merz Aesthetics is known for building unique connections with customers who feel like family. Merz Aesthetics’ global headquarters is in Raleigh, N.C., USA, with a commercial presence in 90 countries worldwide. It is also a part of Merz Group, which was founded in 1908 and is based in Frankfurt, Germany. Learn more at merzaesthetics.com.

Copyright © 2025 Merz Aesthetics GmbH. All rights reserved. MERZ, MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KGaA. ULTHERA, ULTHERAPY and ULTHERAPY PRIME are trademarks and/or registered trademarks of Ulthera Inc. in the EU and/or certain other countries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250123568990/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom